Alex Zhavoronkov, PhD, is the founder, CEO and CBO of a clinical-stage generative AI-powered global biotechnology company Insilico Medicine, which raised over $800 million, nominated 27 preclinical candidates, 11 reached clinical stage. He is also an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging. Since 2014, he published over 300 peer-reviewed academic publications and 3 books.